ATG15 Antibody

What epitopes should I target when selecting an ATG15 antibody?

When selecting an ATG15 antibody, consider targeting epitopes that will provide the most information about your research question. Atg15 contains a single N-terminal transmembrane domain (residues 13-35) and a GXSXG lipase consensus motif (residues 330-334) . For detecting full-length Atg15, antibodies against C-terminal regions are preferable since this region remains intact after processing. If you're studying Atg15 activation mechanisms, consider antibodies that can distinguish between the unprocessed and Pep4/Prb1-processed forms. Custom antibodies against specific domains may be necessary for specialized applications, as commercial antibodies might not differentiate between processed forms.

How can I validate the specificity of my ATG15 antibody?

Rigorous validation is essential to ensure experimental reliability. First, perform Western blot analysis comparing wild-type and atg15Δ samples—the absence of specific bands in the knockout confirms specificity . Second, compare expression patterns between endogenous Atg15 and epitope-tagged versions (FLAG or GFP) using both your ATG15 antibody and anti-tag antibodies. Third, verify detection of recombinant Atg15 at predicted molecular weights. Note that Atg15 often appears 15-20% larger than predicted on SDS-PAGE even without glycosylation, likely due to its hydrophobic nature . Finally, perform deglycosylation experiments with Endo H to confirm glycosylated forms of the protein.

What are the optimal conditions for ATG15 detection via Western blotting?

For optimal Atg15 detection by Western blotting, samples should be precipitated with 10% TCA and resuspended in sample buffer (50 mM Tris-HCl pH 7.5, 70 mM SDS, 8% glycerol, 20 mM DTT) . Heat samples at 65°C for 15 minutes rather than boiling to prevent aggregation of this transmembrane protein. For Atg15 from yeast, consider using 8-10% gels for better resolution of the different processed forms. Following transfer, block with 5% non-fat milk and incubate with primary antibody at 1:1000 dilution overnight at 4°C. When analyzing glycosylation status, perform parallel samples with Endo H treatment at 30°C for 2 hours before SDS-PAGE separation .

How can I detect different processed forms of ATG15 in vacuolar preparations?

Detecting the various processed forms of Atg15 requires careful sample preparation and antibody selection. Purify vacuoles using Ficoll gradient ultracentrifugation as described by Ohsumi and Anraku (1981) . Disrupt vacuoles by freeze-thaw cycles to yield vacuolar lysate containing processed Atg15. For immunodetection, use internally FLAG-tagged Atg15 constructs (e.g., between residues 377-378) which allow monitoring of both N-terminal and C-terminal processing events . This approach enables identification of distinct processed forms ranging from 50-70 kDa. When comparing processed forms, use pep4Δ prb1Δ cells as controls, which accumulate unprocessed Atg15 . Remember that Atg15 typically migrates 15-20% larger than its predicted molecular weight, complicating size estimation.

How can I correlate ATG15 processing with its lipase activity using antibody-based techniques?

To correlate Atg15 processing with lipase activity, combine immunoprecipitation with functional assays. First, immunoprecipitate FLAG-tagged Atg15 from vacuolar lysates using anti-FLAG antibodies. Verify processing state by Western blotting with anti-Atg15 or anti-FLAG antibodies . Then, use the immunoprecipitated material for in vitro lipase assays using NBD-PE as a substrate, followed by thin-layer chromatography to detect hydrolysis products (NBD-LPE and NBD-FFA) . Compare lipase activity between wild-type Atg15 and the catalytically inactive S332A mutant to confirm specificity. Additionally, assess Atg15 from pep4Δ, prb1Δ, and pep4Δ prb1Δ strains to determine the relationship between protease processing and lipase activation .

What approaches can address cross-reactivity issues with ATG15 antibodies in complex cellular fractions?

Cross-reactivity challenges with Atg15 antibodies can be addressed through multiple complementary approaches. First, perform antibody pre-adsorption with lysates from atg15Δ cells to remove antibodies that bind non-specific epitopes. Second, use epitope competition assays with recombinant Atg15 fragments to confirm binding specificity. Third, implement sequential immunoprecipitation strategies—first clearing lysates with pre-immune serum before immunoprecipitating with anti-Atg15 antibodies. For immunofluorescence or immunoelectron microscopy applications where cross-reactivity is problematic, validate specificity using parallel staining of atg15Δ cells and wild-type cells expressing GFP-tagged Atg15 as internal controls . Additionally, when working with vacuolar fractions, account for potential cross-reactivity with other vacuolar hydrolases by including appropriate controls (e.g., pep4Δ, prb1Δ).

How can ATG15 antibodies be used to study the mechanism of autophagosome inner membrane disruption?

To investigate autophagosome inner membrane disruption, combine Atg15 antibody-based detection with functional assays for autophagosome body (AB) disruption. First, isolate ABs from atg15Δ cells expressing autophagy cargo markers like GST-GFP and pre-Ape1 (prApe1) . Then, incubate the isolated ABs with immunopurified active Atg15 or inactive Atg15S332A mutant as a control. Monitor AB membrane disruption by assessing the appearance of degraded Ape1 (dApe1) and free GFP via Western blotting with appropriate antibodies . This approach allows direct examination of Atg15's membrane-disrupting activity. Anti-Atg15 antibodies can also be used for immunofluorescence to track Atg15 localization to ABs during autophagy induction, providing spatial information about the disruption mechanism.

What controls are essential when using ATG15 antibodies to study its role in the context of other autophagy proteins?

When studying Atg15 in the context of other autophagy proteins, several essential controls must be included. First, use atg15Δ cells as negative controls to establish baseline signals and confirm antibody specificity. Second, include atg15Δ cells expressing Atg15-S332A (catalytically inactive mutant) to distinguish between lipase activity and potential structural roles . Third, utilize pep4Δ prb1Δ mutants to accumulate unprocessed Atg15 and intact ABs as processing controls . Fourth, when examining interactions with other autophagy machinery, include relevant atg mutants (e.g., atg5Δ, atg9Δ) to place Atg15 function in the autophagy pathway context. Finally, when assessing whether Atg15 antibodies interfere with protein-protein interactions, include isotype-matched control antibodies at equivalent concentrations.

How can I optimize co-immunoprecipitation protocols to study ATG15 interaction with vacuolar proteases?

Optimizing co-immunoprecipitation (co-IP) for studying Atg15 interaction with vacuolar proteases requires careful consideration of the membrane-associated nature of Atg15 and the proteolytic activity of its binding partners. First, use membrane-compatible lysis buffers containing 1% digitonin or 0.5% NP-40 to solubilize Atg15 without disrupting protein-protein interactions. Second, include protease inhibitors tailored to vacuolar proteases (e.g., pepstatin A for Pep4, PMSF for Prb1) but at concentrations that won't completely abolish activity if studying processing events . Third, perform reciprocal co-IPs using antibodies against both Atg15 and the vacuolar proteases, comparing results from wild-type and catalytically inactive mutants (Atg15-S332A, pep4Δ, prb1Δ). Finally, confirm interactions using proximity ligation assays or bimolecular fluorescence complementation as orthogonal methods that can detect transient interactions occurring during Atg15 processing.

What sample preparation techniques optimize ATG15 antibody performance in different applications?

Sample preparation techniques significantly impact Atg15 antibody performance across different applications. For Western blotting, TCA precipitation followed by resuspension in SDS sample buffer and moderate heating (65°C for 15 minutes) provides optimal results . For immunofluorescence, aldehyde fixation followed by mild detergent permeabilization preserves Atg15's membrane association while allowing antibody access. When preparing samples for immunoprecipitation, use digitonin-based lysis buffers (1-1.5%) to maintain membrane protein complexes intact. For vacuolar preparations, employ the Ficoll gradient method followed by osmotic lysis to release luminal contents while preserving membrane-associated proteins . When studying glycosylated forms of Atg15, parallel samples with and without Endo H treatment allow for discrimination between glycosylated and non-glycosylated species . For cryo-immunoelectron microscopy, rapid freezing followed by freeze-substitution fixation preserves Atg15 antigenicity better than traditional chemical fixation methods.

How can I troubleshoot weak or absent ATG15 signals in immunoblotting experiments?

When troubleshooting weak or absent Atg15 signals in immunoblotting, consider several factors specific to this transmembrane phospholipase. First, verify expression levels—endogenous Atg15 is often expressed at low levels, necessitating multicopy plasmid expression for clear detection . Second, optimize protein extraction—TCA precipitation (10% TCA with 1.8 μg/ml tRNA as carrier) more effectively recovers hydrophobic proteins like Atg15 compared to standard methods . Third, avoid boiling samples, which causes aggregation of membrane proteins; instead, incubate at 65°C for 15 minutes . Fourth, consider the processing state—in wild-type cells, Atg15 is rapidly processed, resulting in multiple lower-molecular-weight bands rather than a single strong signal. Compare with pep4Δ prb1Δ samples where unprocessed Atg15 accumulates . Fifth, optimize transfer conditions—use mixed methanol/SDS transfer buffers and PVDF membranes for hydrophobic proteins. Finally, consider epitope accessibility—processing by Pep4/Prb1 may remove the epitope recognized by some antibodies, necessitating the use of internally tagged constructs or domain-specific antibodies.

What techniques can distinguish between active and inactive forms of ATG15 using antibody-based methods?

Distinguishing active from inactive Atg15 forms requires combining antibody detection with functional analysis. First, use immunoprecipitation with anti-FLAG antibodies to isolate Atg15-FLAG from vacuolar preparations, followed by in vitro lipase assays using NBD-PE as substrate . Active Atg15 will produce NBD-LPE and NBD-FFA detectable by thin-layer chromatography, while inactive forms won't . Second, combine this with Western blotting of parallel samples to correlate specific processed forms with activity. Third, develop phospho-specific antibodies targeting potential regulatory phosphorylation sites on Atg15, as phosphorylation often regulates lipase activity. Fourth, use antibodies recognizing conformational epitopes that are exposed only in the active state. Fifth, employ bimolecular fluorescence complementation with split fluorescent protein tags on Atg15 domains that separate upon activation, using antibodies against the tags to quantify activation states. Finally, use proximity labeling approaches (BioID or APEX) coupled with antibody detection to identify proteins specifically interacting with active Atg15 forms.

How can ATG15 antibodies be used to track the trafficking of ATG15 from the ER to vacuoles?

Tracking Atg15 trafficking from the ER to vacuoles requires strategic antibody application in various microscopy and biochemical approaches. First, perform immunofluorescence microscopy with anti-Atg15 antibodies alongside organelle markers (Sec61 for ER, Pep12 for endosomes, Pho8 for vacuoles) at different timepoints following autophagy induction . Second, use subcellular fractionation to isolate ER, Golgi, endosomal, and vacuolar fractions, followed by immunoblotting to quantify Atg15 distribution across compartments. Third, employ pulse-chase experiments with metabolic labeling combined with immunoprecipitation to track newly synthesized Atg15. Fourth, utilize split-GFP complementation between Atg15 and compartment-specific markers, detecting the resulting fluorescence with anti-GFP antibodies. Finally, for high-resolution tracking, implement correlative light and electron microscopy (CLEM) with immuno-gold labeling of Atg15 to visualize trafficking intermediates at ultrastructural resolution . This multi-modal approach provides comprehensive spatiotemporal information about Atg15 trafficking through the secretory and MVB pathways.

What strategies can determine if conflicting results using different ATG15 antibodies reflect real biological differences?

When different Atg15 antibodies yield conflicting results, systematic investigation is required to determine whether the discrepancies reflect genuine biological variations or technical artifacts. First, map the exact epitopes recognized by each antibody through epitope mapping techniques or manufacturer documentation. Second, test antibody performance across different experimental conditions using positive controls (overexpressed Atg15) and negative controls (atg15Δ samples) . Third, perform side-by-side comparisons using internally tagged Atg15 constructs that can be detected by both anti-tag and anti-Atg15 antibodies . Fourth, validate findings using orthogonal methods that don't rely on antibodies, such as mass spectrometry for protein identification or fluorescently tagged Atg15 for localization studies. Fifth, systematically test how genetic backgrounds (wild-type, pep4Δ, prb1Δ) affect antibody detection patterns to identify condition-dependent epitope accessibility . Finally, conduct cross-validation experiments in different model systems to distinguish conserved biological phenomena from species-specific or antibody-specific artifacts.

How can super-resolution microscopy with ATG15 antibodies provide insights into autophagosome membrane disruption?

Super-resolution microscopy combined with Atg15 antibodies offers unprecedented insights into autophagosome membrane disruption mechanisms. First, implement direct stochastic optical reconstruction microscopy (dSTORM) using primary anti-Atg15 antibodies and fluorophore-conjugated secondary antibodies to achieve ~20 nm resolution of Atg15 distribution on autophagosome membranes. Second, use structured illumination microscopy (SIM) with dual labeling of Atg15 and autophagosomal markers (Atg8) to visualize the temporal relationship between Atg15 recruitment and membrane disruption events. Third, employ expansive microscopy to physically magnify samples, enhancing effective resolution while preserving the spatial relationship between Atg15 and membrane structures. Fourth, implement correlative light and electron microscopy combining immunofluorescence of Atg15 with electron tomography to correlate protein localization with membrane ultrastructure during disruption . Fifth, perform live-cell super-resolution imaging using split fluorescent protein complementation between Atg15 and autophagy markers to capture the dynamics of Atg15-mediated disruption. These approaches collectively provide multiscale spatial and temporal information about how Atg15 interfaces with autophagosomal membranes during the disruption process.